Education
About Us
Working with TipRanks
Follow Us
Heron Therapeutics (HRTX)
NASDAQ:HRTX
RESEARCH TOOLSreports
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.02Last Year’s EPS
-0.02Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: 29.82%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Positive
The call highlighted significant achievements in profitability, revenue growth, and operational efficiency, alongside successful product developments and legal victories. However, challenges remain with increased competition, cash flow management, and ongoing legal and R&D expenses.Company Guidance
In the Heron Therapeutics Q4 2024 conference call, the company reported a successful year, achieving profitability for both the fourth quarter and the full year. Heron saw net revenues of $144.2 million for 2024, marking a 14% year-over-year increase, and delivered an adjusted EBITDA of $8.6 million. The Oncology franchise, including CINVANTI, generated over $100 million, up from $94.8 million in 2023. ZYNRELEF also showed strong performance with Q4 net revenues reaching $8.5 million, a 33% increase from Q3. Looking ahead, Heron provided guidance for 2025 with expected product revenues net ranging from $153 million to $163 million and adjusted EBITDA between zero to $8 million. The company anticipates growth driven by the CrossLink partnership, expanded product labeling, and the implementation of the NOPAIN Act, alongside maintaining financial efficiency with a cash balance of $59 million at the end of 2024.Achievement of Profitability
Heron Therapeutics achieved profitability for both Q4 2024 and the full year, with a net income of $3.6 million for the quarter and adjusted EBITDA of $8.6 million.
Strong Revenue Growth
Net revenues for 2024 reached $144.2 million, marking a 14% year-over-year increase. CINVANTI revenues rebounded in Q4, and ZYNRELEF achieved record net revenues of $8.5 million, a 33% increase from Q3.
Operational Efficiency Improvements
Operating expenses have been reduced by over $80 million since 2022, with SG&A expenses decreasing significantly. Gross margins improved from 49% to approximately 73%.
Successful Product Developments
Expanded product labeling for ZYNRELEF and launched the Vial Access Needle (VAN) in December 2024, receiving positive feedback.
Legal Victory
The U.S. District Court ruled in favor of Heron in its patent lawsuit against Fresenius Kabi, upholding the validity of the CINVANTI patents.
---
HRTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HRTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $1.71 | $2.05 | +19.88% |
| Nov 12, 2024 | $1.84 | $1.28 | -30.43% |
| Aug 06, 2024 | $2.67 | $2.00 | -25.09% |
| May 07, 2024 | $2.84 | $2.87 | +1.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Heron Therapeutics (HRTX) report earnings?
Heron Therapeutics (HRTX) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Heron Therapeutics (HRTX) earnings time?
Heron Therapeutics (HRTX) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HRTX EPS forecast?
HRTX EPS forecast for the fiscal quarter 2025 (Q1) is -0.02.
---
